gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RCELHealthcareSurgical Instruments

Avita Medical, Inc. Common Stock (RCEL)

$16.32+6.46%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$16.18▲ 328.04% in range
Nov 3, 2025Low $3.27 · High $16.71Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Avita Medical closed at $16.32 on Nov 4, up 6.46%, 2.3% below its 52-week closing high. Volume of 536.5K shares was 1.25× its 20-day average (close to normal).

Split-adjusted performance: +25.6% over one month, +269.2% over six months, +331.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $21.70M, up 17.8% from a year earlier, with a net margin of -35.3%.

Short interest was 2.8M shares at the Oct 15 settlement, down 1.8% from the prior report (9.4% of float, 7.6 days to cover).

Market cap$504.7M30.9M shares
Revenue · quarter$21.7M+17.8% YoY
Diluted EPS$-0.25—
P/E · TTM—P/S 6.7×
Net margin-35.3%Gross 81.9%
Dividend yieldNone
52-week range3.27 – 16.71−2.3% from high
Volume536.5K1.25× 20-day avg
Volatility · 60d69.1%Annualised
Short % of float9.4%7.6 days to cover
Net cash-$35.5MCash $11.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.1%1M +25.6%3M +243.6%6M +269.2%YTD +373.0%1Y +331.7%3Y +74.2%5Y −3.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum100
Revenue growth71
Net margin35
Value (low P/E)—
Size61

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short2.8M−1.8% vs prior
Days to cover7.6Settled Oct 15
% of float9.4%
Short vol. 10d58.4%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RCELAvita Medical$16.32+6.46%+269.2%+17.8%−35.3%—$504.7M
DCTHDelcath Systems$14.82+2.92%+31.6%+20.6%9.2%966.6$514.2MCompare
ANGOAngioDynamics$12.25+4.43%+10.9%+6.9%−8.8%—$515.2MCompare
CERSCerus$2.42+3.21%−6.8%+6.3%−0.9%—$486.7MCompare
SGHTSight Sciences$9.68+2.76%+125.1%+19.5%−19.0%—$533.3MCompare
MDXGMiMedx Group$3.20−1.54%−12.6%−45.2%−13.9%—$467.0MCompare
NPCENeuropace$13.34+8.37%−26.4%+17.1%−27.2%—$457.9MCompare
SSIISS Innovations International$2.27−2.58%−44.2%+39.4%−19.1%—$455.1MCompare
CARLCarlsmed$16.09+11.74%+63.5%—−55.5%—$439.3MCompare

News about Avita Medical

All news →
AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire Inc. · Aug 7, 2026Neutral

Quick answers

What does Avita Medical do?
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts.
What is RCEL's market cap?
$504.73M, based on the Nov 4 close of $16.32.
Does Avita Medical pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RCEL is sold short?
2.8M shares, 9.4% of float, as of Oct 15, 2026.
What sector is RCEL in?
Healthcare, in the Surgical Instruments industry.

About Avita Medical

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

HQ: Valencia, CA226 employeesListed Mar 8, 2012avitamedical.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology